These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 26024586)

  • 21. Alkaptonuria.
    Lorenzini S; Mannoni A; Selvi E
    N Engl J Med; 2003 Apr; 348(14):1408; author reply 1408. PubMed ID: 12672874
    [No Abstract]   [Full Text] [Related]  

  • 22. Characterizing the alkaptonuria joint and spine phenotype and assessing the effect of homogentisic acid lowering therapy in a large cohort of 87 patients.
    Ranganath LR; Khedr M; Vinjamuri S; Gallagher JA
    J Inherit Metab Dis; 2021 May; 44(3):666-676. PubMed ID: 33452825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alkaptonuria: treasure your exceptions.
    Cox TM
    J Inherit Metab Dis; 2011 Dec; 34(6):1113-4. PubMed ID: 21938512
    [No Abstract]   [Full Text] [Related]  

  • 24. NTBC and alkaptonuria.
    Anikster Y; Nyhan WL; Gahl WA
    Am J Hum Genet; 1998 Sep; 63(3):920-1. PubMed ID: 9718357
    [No Abstract]   [Full Text] [Related]  

  • 25. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.
    Tinti L; Spreafico A; Braconi D; Millucci L; Bernardini G; Chellini F; Cavallo G; Selvi E; Galeazzi M; Marcolongo R; Gallagher JA; Santucci A
    J Cell Physiol; 2010 Oct; 225(1):84-91. PubMed ID: 20648626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.
    Cox TF; Ranganath L
    J Inherit Metab Dis; 2011 Dec; 34(6):1153-62. PubMed ID: 21744089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum markers in alkaptonuria: simultaneous analysis of homogentisic acid, tyrosine and nitisinone by liquid chromatography tandem mass spectrometry.
    Hughes AT; Milan AM; Davison AS; Christensen P; Ross G; Gallagher JA; Dutton JJ; Ranganath LR
    Ann Clin Biochem; 2015 Sep; 52(Pt 5):597-605. PubMed ID: 25628464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alkaptonuria.
    Yancovitz M; Anolik R; Pomeranz MK
    Dermatol Online J; 2010 Nov; 16(11):6. PubMed ID: 21163157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience of nitisinone for the pharmacological treatment of hereditary tyrosinaemia type 1.
    Santra S; Baumann U
    Expert Opin Pharmacother; 2008 May; 9(7):1229-36. PubMed ID: 18422479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nutritional interventions for patients with alkaptonuria: A minireview.
    Imrich R; Zatkova A; Lukacova O; Sedlakova J; Zanova E; Vlcek M; Penesova A; Radikova Z; Havranova A; Ranganath L
    Endocr Regul; 2023 Jan; 57(1):61-67. PubMed ID: 36966367
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Suitability of nitisinone for alkaptonuria.
    Häberle J
    Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
    [No Abstract]   [Full Text] [Related]  

  • 32. Characterising the arthroplasty in spondyloarthropathy in a large cohort of eighty-seven patients with alkaptonuria.
    Ranganath LR; Gallagher JA; Davidson J; Vinjamuri S
    J Inherit Metab Dis; 2021 May; 44(3):656-665. PubMed ID: 33314212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alkaptonuria - Many questions answered, further challenges beckon.
    Davison AS; Hughes AT; Milan AM; Sireau N; Gallagher JA; Ranganath LR
    Ann Clin Biochem; 2020 Mar; 57(2):106-120. PubMed ID: 31529982
    [No Abstract]   [Full Text] [Related]  

  • 34. Determinants of tyrosinaemia during nitisinone therapy in alkaptonuria.
    Ranganath LR; Milan AM; Hughes AT; Davison AS; M K; Norman BP; Bou-Gharios G; Gallagher JA; Imrich R; Arnoux JB; Rudebeck M; Olsson B
    Sci Rep; 2022 Sep; 12(1):16083. PubMed ID: 36167967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of Potential Inhibitors for the Treatment of Alkaptonuria Using an Integrated In Silico Computational Strategy.
    Zaib S; Rana N; Hussain N; Ogaly HA; Dera AA; Khan I
    Molecules; 2023 Mar; 28(6):. PubMed ID: 36985595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nitisinone causes acquired tyrosinosis in alkaptonuria.
    Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
    J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Old treatments for new insights and strategies: proposed management in adults and children with alkaptonuria.
    Arnoux JB; Le Quan Sang KH; Brassier A; Grisel C; Servais A; Wippf J; Dubois S; Sireau N; Job-Deslandre C; Ranganath L; de Lonlay P
    J Inherit Metab Dis; 2015 Sep; 38(5):791-6. PubMed ID: 25860819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Comprehensive LC-QTOF-MS Metabolic Phenotyping Strategy: Application to Alkaptonuria.
    Norman BP; Davison AS; Ross GA; Milan AM; Hughes AT; Sutherland H; Jarvis JC; Roberts NB; Gallagher JA; Ranganath LR
    Clin Chem; 2019 Apr; 65(4):530-539. PubMed ID: 30782595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and biochemical assessment of depressive symptoms in patients with Alkaptonuria before and after two years of treatment with nitisinone.
    Davison AS; Harrold JA; Hughes G; Norman BP; Devine J; Usher J; Hughes AT; Khedr M; Gallagher JA; Milan AM; J C G H; Ranganath LR
    Mol Genet Metab; 2018 Sep; 125(1-2):135-143. PubMed ID: 30049652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In brief: Nitisinone (Orfadin) for hereditary tyrosinemia.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):e132. PubMed ID: 27701365
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.